Stabilizing Sevoflurane Against Acid Degradation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Fluoroether compounds, such as sevoflurane, undergo degradation due to contact with acid substances, leading to the formation of toxic products like hydrofluoric acid and 1,1,1,3,3,3-hexafluoroisopropanol, which poses risks to patient safety and complicates their storage and use in anesthesia.
Innovation Solution
The use of polyalcohols like propylene glycol, polyethylene glycol, hexylene glycol, and menthol as stabilizers to prevent degradation by forming stable compositions that inhibit the formation of toxic products when exposed to acid substances, including Lewis acids and CO2 absorbents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If fluoroether compounds are stored in contact with acid substances (such as CO2 absorbents or glass surfaces), then the storage and handling become simplified, but the compound undergoes degradation forming toxic products
Solution Approach 1:
The patent introduces stabilizer agents (such as amine compounds, phosphine compounds, or sulfur compounds) as intermediary substances that contact the acid substances instead of the fluoroether compound. These stabilizers preferentially react with Lewis acids and CO2 absorbents, forming a protective barrier that prevents direct contact between the acid substances and the fluoroether compound, thereby preventing degradation while allowing storage in常规 containers
Solution Approach 2:
The patent converts the harmful acid substances (Lewis acids, CO2 absorbents) into beneficial protective elements by using them to react with the stabilizer agents. The reaction products of stabilizers with acid substances form a protective layer that actually protects the fluoroether compound from degradation, transforming the harmful acid substances into part of the protection system
2Reliability
If stabilizer agents are added to prevent degradation, then the stability and safety of fluoroether compounds improve, but the composition becomes more complex
Solution Approach 1:
The patent optimizes the concentration parameters of stabilizer agents to achieve effective stabilization with minimal amounts. By carefully controlling the stabilizer concentration (typically 0.001-5% w/w), the patent maintains high stability while minimizing the impact on composition complexity and ensuring the fluoroether compound remains the dominant component
Solution Approach 2:
The patent creates a composite pharmaceutical composition that integrates the fluoroether compound with stabilizer agents and other pharmaceutical excipients into a unified stable formulation. This composite approach allows the stabilizers to be seamlessly incorporated without significantly increasing complexity, as they work synergistically with other formulation components
3Productivity
If CO2 absorbents with high water content are used for effective CO2 absorption, then the CO2 absorption efficiency improves, but the degradation of fluoroether compounds increases
Solution Approach 1:
The stabilizer agents act as intermediaries between the high-water-content CO2 absorbents and the fluoroether compounds. These stabilizers preferentially interact with the CO2 absorbent materials (such as soda lime or baralime), preventing them from catalyzing the degradation of fluoroether compounds while maintaining their CO2 absorption functionality
Solution Approach 2:
The stabilizer agents provide preliminary protection against degradation by being present in the system before any degradation can occur. They preemptively neutralize or complex with the acid catalysts in the CO2 absorbents, preventing the initiation of degradation pathways even when high-water-content absorbents are used
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These stabilizers effectively prevent the degradation of sevoflurane, maintaining its purity and safety for inhalation anesthesia by completely inhibiting the formation of harmful compounds, even in the presence of acid substances, thus ensuring the compound's stability and efficacy in various storage conditions.
Implementation Method 1
a stable anesthetic composition comprising a fluoroether compound and an effective amount of at least one stabilizing agent selected from the group constituted of polyalcohols and saturated cyclic alcohols
Data Source
AI summary
The present invention has as objective the stabilization of a fluoroether compound against degradation by acid substances. The stabilizers proposed are selected among propylene glycol, polyethylene glycol, hexylene glycol, 1,3-butylene glycol and a saturated cyclic alcohol preferably menthol and are used for preparing stable pharmaceutical compositions of a fluoroether compound. Method for stabilizing a fluoroether compound and use of stabilizers agents for precluding the degradation of a fluoroether are also described.